TimesSquare Capital Management LLC Makes New $15.18 Million Investment in CeriBell, Inc. $CBLL

TimesSquare Capital Management LLC purchased a new stake in shares of CeriBell, Inc. (NASDAQ:CBLL) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 780,552 shares of the company’s stock, valued at approximately $15,182,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the period. Strs Ohio acquired a new position in shares of CeriBell in the 1st quarter valued at $27,000. CWM LLC increased its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the period. Tower Research Capital LLC TRC raised its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Finally, Larson Financial Group LLC lifted its position in CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after acquiring an additional 2,680 shares during the period.

Wall Street Analyst Weigh In

Several research firms have weighed in on CBLL. BTIG Research reiterated a “buy” rating and set a $28.00 price target on shares of CeriBell in a research note on Tuesday, August 11th. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Insider Buying and Selling at CeriBell

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the sale, the insider directly owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joseph Michael Taylor sold 13,095 shares of CeriBell stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total value of $306,423.00. Following the transaction, the director owned 48,478 shares of the company’s stock, valued at approximately $1,134,385.20. This represents a 21.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 313,780 shares of company stock worth $6,241,749. Insiders own 17.70% of the company’s stock.

CeriBell Stock Up 4.6%

NASDAQ:CBLL opened at $24.40 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company’s fifty day moving average price is $19.06 and its 200-day moving average price is $19.10. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.44. The firm has a market capitalization of $936.47 million, a P/E ratio of -13.86 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. As a group, equities research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

CeriBell Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.